Key Points
- COO Eben Tessari sold 12,470 shares on November 17 at an average price of $41.24 for proceeds of $514,262.80, leaving him with 22,714 shares — a 35.44% reduction in his holdings.
- The transaction is part of a string of large insider sales by Tessari since September totaling several million dollars; KNSA trades near its 52‑week high, has a market cap of about $3.23B, and carries a consensus analyst rating of “Moderate Buy” with an average price target of $52.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,470 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.24, for a total value of $514,262.80. Following the transaction, the chief operating officer directly owned 22,714 shares of the company's stock, valued at $936,725.36. This trade represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Eben Tessari also recently made the following trade(s):
- On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $37.67, for a total value of $465,902.56.
- On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00.
- On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total transaction of $597,944.00.
- On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.52, for a total transaction of $3,028,825.92.
- On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74.
- On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total transaction of $535,730.50.
Kiniksa Pharmaceuticals International Stock Performance
Shares of KNSA stock opened at $42.58 on Thursday. The firm's 50-day moving average is $38.25 and its 200-day moving average is $32.70. The stock has a market cap of $3.23 billion, a price-to-earnings ratio of 95.04 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $42.30.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts' consensus estimates of $0.31 by ($0.08). The business had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company's revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.18) EPS. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.
Institutional Trading of Kiniksa Pharmaceuticals International
A number of institutional investors have recently modified their holdings of the stock. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International during the third quarter worth about $32,000. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Quarry LP bought a new stake in Kiniksa Pharmaceuticals International during the third quarter worth $44,000. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 582.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company's stock valued at $53,000 after purchasing an additional 1,159 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the company. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a "buy" rating and a $60.00 price target on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, November 2nd. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a research report on Thursday, September 25th. Finally, Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $52.00.
Check Out Our Latest Stock Analysis on Kiniksa Pharmaceuticals International
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
